A067630 Stock Overview
HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally.
HLB Life Science Co., Ltd. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₩9,060.00|
|52 Week High||₩13,320.00|
|52 Week Low||₩8,260.00|
|1 Month Change||5.35%|
|3 Month Change||-8.11%|
|1 Year Change||-25.85%|
|3 Year Change||-30.45%|
|5 Year Change||-14.93%|
|Change since IPO||425.70%|
Recent News & Updates
HLB Life Science (KOSDAQ:067630) Has Debt But No Earnings; Should You Worry?Apr 12
Did You Participate In Any Of HLB Life Science's (KOSDAQ:067630) Incredible 442% Return?Feb 14
Is HLB Life Science (KOSDAQ:067630) A Risky Investment?Jan 10
We're Not So Sure You Should Rely on HLB Life Science's (KOSDAQ:067630) Statutory EarningsDec 06
|A067630||KR Healthcare||KR Market|
Return vs Industry: A067630 underperformed the KR Healthcare industry which returned -1.7% over the past year.
Return vs Market: A067630 underperformed the KR Market which returned 11% over the past year.
|A067630 Average Weekly Movement||5.4%|
|Healthcare Industry Average Movement||6.4%|
|Market Average Movement||5.9%|
|10% most volatile stocks in KR Market||12.3%|
|10% least volatile stocks in KR Market||3.2%|
Stable Share Price: A067630 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: A067630's weekly volatility (5%) has been stable over the past year.
About the Company
HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, thyroid cancer, mesothelioma, and neuroendocrine tumors; Seclidemstat, a novel epigenetic oral small molecule for target therapy to normalize gene expression and suppress tumor growth in various solid tumors, such as lung, breast, and prostate cancer; and Tegavivint, inhibitor of the Wnt/ß-catenin for the treatment of desmoid tumors, acute myeloid leukemia, osteosarcoma, and a range of solid tumor types. In addition, the company develops LifeLiver, an extracorporeal bioartificial liver system; HepaStem, a heterologous human adult liver-derived progenitor cell therapy; and HLBLS-200, a biocompatible polysaccharide-based powders that forms adhesive hemostasis upon contact with blood.
HLB Life Science Co., Ltd. Fundamentals Summary
|A067630 fundamental statistics|
Is A067630 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A067630 income statement (TTM)|
|Cost of Revenue||₩123.11b|
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
|Earnings per share (EPS)||-457.99|
|Net Profit Margin||-38.74%|
How did A067630 perform over the long term?See historical performance and comparison